Cangene and NIH team up against SARS

Toronto, ON and Winnipeg, MB October 17, 2003 Biotech firm Cangene says it has signed a research and development contract with the National Institute of Allergy and Infectious Diseases (NIAID) to develop a hyperimmune specific for the virus that causes severe acute respiratory syndrome (SARS). NIAID, part of the United States National Institutes of Health, will supply the plasma and funding for the project.

“One component of Cangene’s multi-faceted growth strategy is to develop hyperimmunes that address emerging medical and biodefence concerns,” says Dr John Langstaff, the company’s president and chief executive officer.